New osteoporosis drug copycat tested in healthy women
NCT ID NCT07497503
First seen Jun 27, 2026 · Last updated Jul 17, 2026 · Updated 2 times
Summary
This early-stage trial is testing whether a new drug called B-3E07 works the same as the approved osteoporosis drug Forsteo. 48 healthy adult women will receive a single injection of each drug in random order. The main goal is to compare how the body absorbs and processes the drugs, and to check for any safety issues.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- B-3E07 (a proposed biosimilar of teriparatide) and Forsteo (teriparatide)
- What this could lead to
- If B-3E07 is shown to be similar to Forsteo, it could become a more affordable option for treating osteoporosis.
- What could go wrong
- This is an early phase 1 study in only 48 healthy volunteers, not patients. It only measures drug levels and safety, not whether the drug actually treats disease. Biosimilars can sometimes differ in effectiveness or side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Veritus Research
RECRUITINGBayswater, Victoria, 3153, Australia
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a new oral drug pass its first safety hurdle?
- Can a new drug play nice with common medicines? a trial investigates
- Could a new pill quiet chronic pain? early trial puts it to the test
- Brain waves under pressure: can light uncover the signature of mental work?
- Can acting as patients teach nurses to truly listen?
- Who decides for you? survey asks incarcerated older adults